Rwanda is a frontrunner to become a regional hub for vaccine manufacturing and medical innovation, thanks to the strong vision of the government, and with the support of the European Union through the Global Gateway strategy. Investments in human development where healthy people live on a healthy planet is a key priority of Global Gateway.
Africa is currently critically dependent on global supply chains, importing 99% of its vaccines and over 90% of its medicines. But investments in Rwanda are paving the way for medical self-sufficiency, revolutionising healthcare on the continent and bringing solutions to some of Africa’s healthcare challenges from within the region itself.
Through the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (‘MAV+') the EU is supporting production in Rwanda for the African region. The focus of the collaboration is the creation of a conducive ecosystem for the biotech industry to flourish.
More detailed information available on the Team Europe Initiative on manufacturing and access to vaccines, medicines and health technologies in Africa page.